GNH India, one of India’s leading pharmaceutical wholesalers, has successfully imported a life-saving ‘Orphan’ drug — named so as it is not easily available globally — which is used to fight solid tumours and soft tissue sarcomas.
The medicine, Olaratumab (trade name Lartruvo), is a monoclonal antibody developed by Eli Lilly and Company is directed against the platelet-derived growth factor receptor alpha.
“GNH India has always believed that everyone should have access to proper healthcare and medicines, and we strive to deliver the same to the people irrespective of the global boundaries. In this effort we have aimed to import a rare orphan status drug called, ‘Olaratumab’ that is used to treat soft tissue sarcoma,” said Dr Piyush Gupta, Associate Director, GNH India.
“It gives us tremendous pleasure to be the first Indian specialised wholesaler to provide this life-saving medicine in India and we look forward to many more opportunities,” he added.
This drug is classified ‘Orphan drug’ as it is not available easily world-wide. In February 2015, the European Medicines Agency assigned Olaratumab ‘orphan drug’ status for the treatment of soft-tissue sarcoma.
The European Commission granted a conditional marketing authorisation, based on a phase II study, valid throughout the European Union, on November 9, 2016.
GNH India is an independent and professionally run full-line pharma wholesaler who ships over 1,35,000 product lines to more than 180 countries worldwide.
The company is fully licensed by state FDA (Food and Drug Administration) and is registered with FIEO (Federation of Indian export) and PHARMEXCIL (Pharmaceutical Export Promotion Council).